Two-Year Efficacy and Safety Update: Phase III CheckMate 025 Study of Nivolumab vs Everolimus in Patients With Advanced Renal Cell Carcinoma (aRCC). Abstracts from the NCRI Cancer Conferences 2016 - Plimack, E R; Motzer, R J; Escudier, B
et al.